No updates for settling balance for differences on targeted therapy for cancer ‘Tarceva’
The pharmaceutical distribution industry raised complaints since they have not been able to settle balance for differences generated by the drug price cut of ‘Tarceva,’ a Roche Korea’s targeted therapy for cancer.
The Tarceva Tab’s drug price dropped from KRW 49,697 to KRW 34,788 for 100mg and f...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.